to view your mail
Yahoo Finance Plus
U.S. Markets open in 4 hrs 52 mins
Brooks Automation, Inc. (BRKS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
211 reactions on $BRKS conversation
Sign in to post a message.
Anybody have thoughts on the runup? I'm a looong time holder, but this stock is oddly up in just the last 5 days. Even with the most agressive earnings estimate the PE is sky high...
Not long ago this was over $90. Nothing has changed except the price. What an opportunity!!
Down 5% on what news? The economy is strengthening and this is getting crushed? This defies logic
Down 13% on no news, stock manipulation at its finest
Analyst's average price target concensus = $97.50. Let's get this up to triple digits.
Forget about today, yesterday, and last year! The year ahead looks great for semiconductor companies!
As of the market close yesterday I moved Brooks Automation to a solid buy. Almost every tech hardware, software and services company has been involved in a correction for weeks. It could be argued that to a degree some names were pressing upper valuation limits and in a few cases exceeding such limits. Brooks is now in the lower region of fair valued and I would suggest that it should be acquired at or below ~ $24.50 per share, which is essentially the level at which it begins to enter an oversold condition relative to existing global economic prospects and profitability.
i say their will be major profit taking the 1st week of january----stock will definitely trade below 70.00
BRKS selling Cryogenic division. Apparently investors really like the transaction. Stock popping up AH.
How does it drop so drastically after beating everything ?
Anyone else read the entire earnings call transcript besides me? Just removed my sell limit order at 88. I’ll give this one a decade to get to $600/s.
Genewiz is drastically undervalued in this company. Most comps are getting 40-70 price to sales valuation for similar profiles. Is it because investors don't realize Genewiz is baked in here? if so this is a lay up for us savvy investors to price the sum of all parts here.
Look for upgrade.
In long term it will go up. But short term it may go down slightly. I can not risk to hold it. I will be out tomorrow and enter back at 36-37.
BRKS just made the IBD 50 list coming in at no. 38
Hey Kevin - just had chance to read today’s earnings call transcript and was happy to see that my assumption that tax changes would be neutral or slight negative when I replied to your question 15 days ago was wrong. BRKS does project net lower rate going forward which is nice! .... I WAS right in speculating that if team “just” executed this is great environment for success and they did exactly that! Seems like good momentum in both Semi & Life Sciences and the analyst Q’s were IMO even a lot more positive than last Q. Combine positive mo, with high confidence for continued and increasing demand plus hitting the top and bottom line numbers AND a non-Amazon like valuation and this is a HOLD and buy more!
The proceeds of sale are almost $10 per share, and the stock is up $8.75. Wall Street seems not to have performed a sum of the parts analysis, and what about capital gains tax on the sale?
Whenever this dips to the low 20’s it must be bought. The growth potential is underestimated by analysts. They are in two of the hottest sectors in tech and healthcare research and development. Buy and hold this for a 50% gain in the next 12 months.
I know this is a high beta stock but down almost 10% on high volume in one day. Maybe it'll be back up in the next few days but what a rollercoaster this one is.
EBITDA has quadrupled from previous levels and the price has not yet matched. Lots of upside potential here.
Does Elon Musk Really Think Dogecoin Is 'A Hustle?'
Wynn shares fall after missing earnings estimates
Yahoo Finance Video
Fourth stimulus check in jeopardy as payments dwindle
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research